

8th European Chemistry Congress

June 21-23, 2018 | Paris, France

SAR156497 an exquisitely selective inhibitor of aurora kinases

Jean-Christophe Carry
Sanofi, France

The Aurora family of serine/threonine kinases is essential for mitosis. Their crucial role in cell cycle regulation and aberrant expression in a broad range of malignancies have been demonstrated and have prompted intensive search for small molecule aurora inhibitors. Indeed, over ten of them have reached the clinic as potential anticancer therapies. We will report the discovery and optimization of a novel series of tricyclic molecules that has led to SAR156497, an exquisitely selective Aurora A, -B and -C inhibitor with *in vitro* and *in vivo* efficacy. We will also provide insights into its mode of binding to its target proteins from X-Ray data, which could explain its selectivity.

Biography

Jean-Christophe Carry works at Sanofi in Paris, France as a medicinal chemistry group and project leader, in a global scientific platform called integrated drug discovery. Prior to that, he worked in sanofi oncology drug discovery from 2004 to 2014. From 1999 to 2004 he worked at Aventis in the global medicinal chemistry department, being involved in several international collaborations in connection with various therapeutic areas and at Rhône-Poulenc Rorer as a medicinal chemist, in the field of Anti-Infectious diseases from 1992 to 1999. He got his PhD in organic chemistry with Pr G H Posner from the Johns Hopkins University, USA in 1992.

jean-christophe.carry@sanofi.com

Notes: